NeoGenomics (NEO) Launches RaDaR ST to Capture Share in $20B MRD Market

NeoGenomics Inc. (NASDAQ:NEO) is one of the most buzzing stocks to buy with the highest upside potential. On February 25, NeoGenomics officially launched RaDaR ST, a tumor-informed circulating tumor DNA/ctDNA assay designed to detect molecular residual disease/MRD across various solid tumor types. This launch targets a rapidly growing MRD market estimated at over $20 billion, which NeoGenomics believes is currently less than 10% penetrated. By providing patient-specific molecular insights, the test allows ...